Galderma Delivers Strong H1 2022 Results and Continued Innovation Across Its Leading Dermatology Portfolio
Galderma:
Continued strong commercial and financial performance in a resilient market
Galderma delivered continued strong growth across product categories, with net sales up 15% year-on-year on a constant currency basis at 1,914 M USD
Particularly strong performance of Injectable Aesthetics and Dermo-cosmetics product categories with growth of 32% and 31% on a constant currency basis, respectively
Volume as a primary growth driver underpins confidence in the resilience and long-term growth fundamentals of the dermatology market
On track to deliver on 2022 guidance of 12-14% net sales and core EBITDA growth on a constant currency basis
Advancing innovation across its leading derma
